cho phép dược phẩm các công ty vẫn có lợi nhuận [mặc dù kiểm soát giá chặt chẽ trong các thị trường lớn khác và không có khả năng khách hàng ở các thị trường đang phát triển phải trả giá đầy đủ cho các sản phẩm của họ. Nếu áp dụng tại Hoa Kỳ, kiểm soát giá cả có thể biến đổi thị trường dược phẩm toàn cầu, | The failure of one or more major financial institutions remains a real worry and could turn the crisis into systemic failure in the year ahead. Jens Tholstrup Oxford Analytica Continued from page 8 2 Global financial shocks One analyst noted The revenue generated from the US pharma market the largest in the world enables pharma companies to remain profitable despite strict price controls in other major markets and the inability of customers in developing markets to pay full prices for their products. If imposed in the United States price controls could transform the global pharma market including business models and the development of new drugs in the future. The compliance challenges are particularly strong in highly regulated industries such as banking insurance pharma and biotech where the regulatory burden is increasing fast and where firms are feeling pressure to demonstrate a return on investment for long-term risk management initiatives. One banking panelist noted Banks are experiencing significant fatigue around managing the myriad of often redundant compliance and regulatory reporting activities the cost of which is massive and burdensome. Similarly a biotech analyst wrote A mounting regulatory compliance burden in areas such as privacy postmarketing monitoring of drug safety and sales force compliance. poses a management and internal controls challenge to biotech companies. Increasingly companies may seek risk convergence initiatives which allow them to coordinate the various risk and control processes reduce redundancy which drives down costs and perhaps most importantly more comprehensive enterprisewide risk reporting to senior management and the board. As companies become more and more global compliance becomes a greater challenge forcing them to manage diverse regulations in different markets. A specialist in business strategy noted Managing regulations in 10 jurisdictions is one thing. What happens when a firm has significant markets in 30-40 .
